Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compliance Director Ulatowski announces retirement

This article was originally published in The Silver Sheet

Executive Summary

CDRH Office of Compliance Director Tim Ulatowski will retire from FDA at the end of the year, the veteran agency staffer announced in an April 12 memo to staff. An opening for the director position was posted by FDA the same day. A smooth transition is important given CDRH's ambitious agenda for the coming years, Ulatowski said in his memo. "A break in permanent leadership for maybe a few months while all this is occurring would not be helpful," noted Ulatowski, who has been with FDA since 1974 and with the Office of Compliance since 2003. Once the new director is hired, Ulatowski will shift to a temporary advisory role until his retirement. "The fact that Tim has announced his retirement is a very gracious decision on his part, because he has allowed the center leadership to identify his successor and to put his successor in place in a timeframe in which Tim will still be available to mentor his successor," Steve Silverman, senior advisor to the center director, said May 5 at the MedCon medical device conference in Cincinnati

You may also be interested in...



Coronavirus Demanding Focus Of US FDA’s Antiviral, Other Divisions

Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.

Akero Heads To Top Of FGF21 Class In NASH; Genfit Says Pandemic Won’t Delay Phase III

Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.

US VP And CMS Chief Urge In-House Academic Hospital Labs To Share COVID-19 Data With HHS

US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.

Topics

UsernamePublicRestriction

Register

MT036476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel